Top Page
BioNTech SE
(NASDAQ:BNTX)
BioNTech SE (BNTX) vs. SPDR S&P 500 ETF (SPY)
BioNTech SE Business Overview & Revenue Model
BioNTech SE Earnings Call Summary
BioNTech SE Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.15B | 2.75B | 3.82B | 17.31B | 18.98B | 482.30M |
| Gross Profit | 2.60B | 2.21B | 3.22B | 14.32B | 16.07B | 423.00M |
| EBITDA | -103.30M | -367.10M | 1.38B | 13.10B | 15.00B | -105.10M |
| Net Income | -571.60M | -665.30M | 930.30M | 9.43B | 10.29B | 15.20M |
Balance Sheet | ||||||
| Total Assets | 21.34B | 22.53B | 23.01B | 23.28B | 15.83B | 2.32B |
| Cash, Cash Equivalents and Short-Term Investments | 14.53B | 16.78B | 16.55B | 14.06B | 2.07B | 1.35B |
| Total Debt | 245.40M | 254.20M | 219.10M | 212.20M | 301.50M | 240.10M |
| Total Liabilities | 2.86B | 3.12B | 2.76B | 3.22B | 3.94B | 946.80M |
| Stockholders Equity | 18.48B | 19.41B | 20.25B | 20.06B | 11.89B | 1.37B |
Cash Flow | ||||||
| Free Cash Flow | -562.71M | -244.60M | 4.67B | 13.21B | 735.70M | -98.90M |
| Operating Cash Flow | -336.14M | 207.70M | 5.37B | 13.58B | 889.70M | -13.50M |
| Investing Cash Flow | 938.93M | -2.08B | -6.95B | -35.30M | -566.10M | -144.80M |
| Financing Cash Flow | -51.58M | -45.90M | -778.60M | -1.42B | 94.20M | 894.70M |
BioNTech SE Technical Analysis
BioNTech SE Risk Analysis
BioNTech SE Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
83 Outperform | $20.81B | 18.28 | 20.04% | ― | 13.50% | 17.16% | |
81 Outperform | $20.98B | 17.84 | 30.39% | ― | 18.09% | 3563.21% | |
76 Outperform | $20.97B | 14.30 | 28.20% | ― | 24.98% | 127.06% | |
60 Neutral | $13.40B | -4.20 | -29.32% | ― | -56.00% | -38.95% | |
59 Neutral | $15.29B | -40.10 | -14.73% | ― | -83.82% | -109.22% | |
53 Neutral | $24.01B | -38.84 | -2.94% | ― | 7.04% | -25.24% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
BioNTech SE Corporate Events
On January 12, 2026, BioNTech SE announced that it will present a strategic business update at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, outlining a catalyst-rich 2026 centered on rapid advancement of its oncology pipeline and multiple late-stage clinical milestones. Management highlighted plans to have 15 Phase 3 oncology trials underway by year-end, including six new Phase 3 initiations, and expects seven late-stage trial readouts in 2026 across immunomodulators, ADCs and mRNA cancer immunotherapies, alongside early-stage combination data that could shape future regulatory and launch strategies. Backed by a preliminary €17.2 billion cash and securities position, ongoing COVID-19 vaccine revenues, and a network of strategic partners such as Bristol Myers Squibb, Genentech, Duality Biologics and others, BioNTech is positioning itself to transition from a single-product COVID-19 vaccine leader into a financially well-capitalized, multi-product oncology company with at least 17 late-stage data readouts anticipated by 2030 and multiple prospective product launches across several cancer indications.
The most recent analyst rating on (BNTX) stock is a Buy with a $134.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
On January 6, 2026, BioNTech SE reported that CureVac N.V. had completed a previously announced post-offer reorganization related to BioNTech’s exchange offer for all outstanding CureVac shares, resulting in BioNTech becoming the sole owner of CureVac’s business operations and eliminating CureVac’s public shareholder base. In parallel with this transaction, BioNTech amended its Articles of Association—effective December 30, 2025—including updated provisions on share capital and authorization for future capital increases, steps that consolidate control over the acquired CureVac business and provide additional corporate and financing flexibility for BioNTech’s ongoing growth and investment strategy.
The most recent analyst rating on (BNTX) stock is a Buy with a $134.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
On December 18, 2025, BioNTech SE announced it had closed its acquisition of CureVac N.V., completing an exchange offer in which approximately 86.75% of CureVac’s outstanding shares were tendered, with a compulsory acquisition of the remaining shares expected in January 2026 and the subsequent delisting of CureVac. The deal is designed to strengthen BioNTech’s already significant position in the global mRNA field by adding CureVac’s technologies in mRNA design, delivery formulations and manufacturing, supporting BioNTech’s oncology strategy and consolidating two of Germany’s pioneering mRNA players under one umbrella; CureVac will initially continue operating under its existing processes while BioNTech’s leadership, now also forming CureVac’s management board, undertakes strategic and scientific analyses to define the combined group’s future organization and portfolio, with implications for a more integrated and potentially more competitive mRNA innovation platform.
The most recent analyst rating on (BNTX) stock is a Buy with a $134.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
On December 9, 2025, BioNTech SE and Bristol Myers Squibb announced interim results from a global Phase 2 trial evaluating pumitamig, a bispecific antibody, in combination with chemotherapy for treating locally advanced/metastatic triple-negative breast cancer (TNBC). The trial showed promising anti-tumor activity, with a confirmed objective response rate of 61.5% and a disease control rate of 92.3%, irrespective of PD-L1 expression levels. These findings highlight the potential of pumitamig to address the unmet needs in TNBC treatment, especially for patients with PD-L1 low or negative tumors, and support its further investigation in the Phase 3 ROSETTA BREAST-01 trial.
The most recent analyst rating on (BNTX) stock is a Buy with a $151.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
On December 6, 2025, BioNTech SE and OncoC4, Inc. presented promising data from the non-pivotal dose-confirmation stage of their global Phase 3 trial, PRESERVE-003, for gotistobart, a tumor microenvironment-selective regulatory T cell depletion candidate. The trial demonstrated that gotistobart significantly reduced the risk of death by more than half compared to standard chemotherapy in patients with metastatic squamous non-small cell lung cancer (sqNSCLC), showing a clinically meaningful overall survival benefit and a manageable safety profile. The median overall survival for patients treated with gotistobart had not been reached at nearly 15 months of follow-up, compared to 10 months for those on chemotherapy. This development positions gotistobart as a potential chemotherapy-free alternative for sqNSCLC patients with high unmet medical needs, enhancing BioNTech’s standing in the oncology field.
The most recent analyst rating on (BNTX) stock is a Buy with a $151.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
On December 3, 2025, BioNTech SE announced that it has satisfied the minimum condition of its exchange offer for CureVac N.V., with 81.74% of CureVac’s shares tendered. The subsequent offering period has commenced, allowing remaining CureVac shareholders to tender their shares until December 18, 2025. The completion of this exchange offer will lead to a post-offer reorganization, impacting the tradability of CureVac shares and subjecting non-tendering shareholders to a Dutch dividend withholding tax. This strategic move strengthens BioNTech’s position in the biopharmaceutical industry by expanding its portfolio and market reach.
The most recent analyst rating on (BNTX) stock is a Buy with a $151.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
On November 26, 2025, BioNTech SE announced the approval of its exchange offer for all outstanding shares of CureVac N.V., following an extraordinary general meeting held by CureVac on November 25, 2025. The offer, which expires on December 3, 2025, involves an exchange ratio of 0.05363 BioNTech ADS per CureVac share. The transaction aims to strengthen BioNTech’s market position by acquiring at least 80% of CureVac’s shares, with a potential reduction to 75% if conditions are met. This strategic move is expected to enhance BioNTech’s capabilities in the biopharmaceutical industry, benefiting stakeholders by expanding its portfolio and market reach.
The most recent analyst rating on (BNTX) stock is a Buy with a $150.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
On November 11, 2025, BioNTech SE hosted its Innovation Series R&D Day, where it outlined its strategic direction and clinical advancements across its pipeline. The event highlighted BioNTech’s unique approach to innovation and its differentiated clinical strategy in oncology, including the development of mRNA cancer immunotherapies. The presentation emphasized the company’s ongoing efforts to establish Pumitamig1 in foundational tumor types and its partnership with Bristol Myers Squibb. This event reflects BioNTech’s commitment to advancing cancer treatment and its continued impact on the biotechnology industry.
The most recent analyst rating on (BNTX) stock is a Buy with a $151.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
On November 3, 2025, BioNTech SE announced its third-quarter financial results, highlighting a revenue increase to €1.5 billion, despite a net loss of €28.7 million. The company reported progress in its oncology strategy, particularly with the bispecific antibody candidate pumitamig, and launched a variant-adapted COVID-19 vaccine for the 2025/2026 season. BioNTech also raised its full-year revenue guidance to €2.6-2.8 billion, supported by a $1.5 billion payment from its partnership with Bristol Myers Squibb.
The most recent analyst rating on (BNTX) stock is a Buy with a $171.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
On November 3, 2025, BioNTech SE announced its financial results for the three and nine months ending September 30, 2025. The company reported revenues of €1,518.9 million for the third quarter, reflecting a significant increase from the previous year. However, despite the revenue growth, BioNTech experienced an operating loss of €46.9 million for the quarter, attributed to increased research and development expenses and other operating costs. This financial update highlights the company’s ongoing investment in its pipeline and the challenges of balancing revenue growth with operational costs.
The most recent analyst rating on (BNTX) stock is a Buy with a $171.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.
On October 22, 2025, BioNTech SE announced the commencement of a public exchange offer for all outstanding shares of CureVac N.V., as part of a strategic acquisition to enhance its capabilities in mRNA-based cancer immunotherapy. This acquisition is expected to strengthen BioNTech’s research, development, manufacturing, and commercialization efforts, marking a significant milestone in its oncology strategy. The transaction, valued at approximately $1.25 billion, aims to create long-term value for shareholders and advance the development of innovative cancer treatments.
The most recent analyst rating on (BNTX) stock is a Buy with a $130.00 price target. To see the full list of analyst forecasts on BioNTech SE stock, see the BNTX Stock Forecast page.